Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis
A Rizzo, A Cusmai, F Giovannelli, S Acquafredda… - Cancers, 2022 - mdpi.com
Simple Summary The current meta-analysis highlighted that proton pump inhibitors (PPIs)
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors …
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors …
Programmed death receptor (PD-) 1/PD-ligand (L) 1 in urological cancers: the “all-around warrior” in immunotherapy
Q Liu, Y Guan, S Li - Molecular cancer, 2024 - Springer
Abstract Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1
(PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is …
(PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is …
Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma
V Mollica, M Santoni, MR Matrana, U Basso… - Targeted Oncology, 2022 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) represent the standard of care as
first-or second-line treatment in patients with renal cell carcinoma (RCC). Proton pump …
first-or second-line treatment in patients with renal cell carcinoma (RCC). Proton pump …
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
Y Tomita, Y Goto, S Sakata, K Imamura… - …, 2022 - Taylor & Francis
Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate …
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate …
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
AM Hopkins, G Kichenadasse, RA McKinnon… - British Journal of …, 2022 - nature.com
Abstract Background Proton pump inhibitors (PPIs) are commonly used concomitant to
cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut …
cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut …
Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
S Lopes, L Pabst, A Dory, M Klotz, B Gourieux… - Frontiers in …, 2023 - frontiersin.org
Introduction Gut microbiota can significantly affect the effectiveness of immune checkpoint
inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival …
inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival …
[HTML][HTML] Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five …
AM Hopkins, S Badaoui, G Kichenadasse… - Journal of Thoracic …, 2022 - Elsevier
Introduction Gut dysbiosis may reduce immune checkpoint inhibitor (ICI) efficacy. Antibiotics
and proton pump inhibitors (PPIs) are commonly used drugs causing gut dysbiosis. There is …
and proton pump inhibitors (PPIs) are commonly used drugs causing gut dysbiosis. There is …
Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced
urothelial cancer. However, a significant number of patients do not respond to ICI, and the …
urothelial cancer. However, a significant number of patients do not respond to ICI, and the …
An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers …
C Liu, H Guo, H Mao, J Tong, M Yang, X Yan - Frontiers in Oncology, 2022 - frontiersin.org
Background Although immune checkpoint inhibitors (ICIs) have revolutionized the current
anticancer therapies, a considerable proportion of patients are found to hardly benefit from …
anticancer therapies, a considerable proportion of patients are found to hardly benefit from …
Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer
BD Qin, XD Jiao, XC Zhou, B Shi, J Wang, K Liu… - …, 2021 - Taylor & Francis
Background The present study aimed to evaluate the effects of concomitant proton pump
inhibitor (PPI) use on immune checkpoint inhibitor (ICI) efficacy among advanced cancer …
inhibitor (PPI) use on immune checkpoint inhibitor (ICI) efficacy among advanced cancer …